GlassScriptPhysician profile
Lindsay D Mehring
NPI 1801021068
$1,685.19
in general payments reported to CMS, 2019-2025
18 companies · $413 in 2025
The $413 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $27.69 · 2021: $80.18 · 2022: $207 · 2023: $604 · 2024: $353 · 2025: $413.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,370.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $688.16 | 2023-2025 | Lifevest |
| Heartflow, INC. | $194.52 | 2025 | |
| Janssen Pharmaceuticals, INC | $190.64 | 2020-2024 | Xarelto |
| Shockwave Medical, INC | $118.15 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $65.40 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $60.76 | 2020-2023 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $57.75 | 2022-2025 | Wainua, Farxiga |
| Novartis Pharmaceuticals Corporation | $50.02 | 2023 | |
| Lexicon Pharmaceuticals, INC. | $48.79 | 2023 | Inpefa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.72 | 2023-2025 | Jardiance |
| Amarin Pharma, INC. | $37.30 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $28.21 | 2023 | Uptravi |
| Abbott Laboratories | $24.12 | 2022 | |
| Novo Nordisk INC | $18.73 | 2025 | Wegovy |
| Amgen INC. | $16.45 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $16.17 | 2024 | Arcalyst |
| Bracco Diagnostics INC. | $14.00 | 2021 | |
| Terumo Medical Corporation | $13.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Mehring listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.